19.07 13:53 | dpa-AFX: Bristol Myers Squibb Receives EMA Validation For Opdivo Plus Yervoy For Treatment Of HCC |
19.07 13:13 | dpa-AFX: *BRISTOL MYERS: EMA VALIDATES APPLICATION FOR OPDIVO + YERVOY FOR 1ST-LINE TREATMENT OF UNRESECTABLE OR ADVANCED HEPATOCELLULAR CARCINOMA |
10.07 09:52 | dpa-AFX: *BARCLAYS SENKT ZIEL FÜR BRISTOL-MYERS SQUIBB AUF 41 (43) USD - 'EQUAL WEIGHT' |
10.07 09:52 | dpa-AFX: *BARCLAYS CUTS BRISTOL-MYERS SQUIBB PRICE TARGET TO 41 (43) USD - 'EQUAL WEIGHT' |
18.06 22:21 | dpa-AFX: *BRISTOL MYERS SQUIBB ELECTS MICHAEL MCMULLEN TO BOARD OF DIRECTORS |
18.06 13:10 | dpa-AFX: *BRISTOL-MYERS SQUIBB CO. (BMY) DECLARES QUARTERLY DIVIDEND OF $ 0.60, RECORD DATE 7/5/2024 |
18.06 13:04 | dpa-AFX: *BRISTOL MYERS SQUIBB DECLARES QUARTERLY DIVIDEND OF $0.60/SHR; RECORD JUY 5/PAYABLE AUG 1 |
12.06 09:07 | dpa-AFX: *EVOTEC TESTEN MIT +3,7% DIE 21-TAGE-LINIE - HOCH SEIT ENDE MAI |
12.06 07:47 | Evotec erhält Forschungszahlung von 20 Mio USD von Myers Squibb |
12.06 07:43 | dpa-AFX: *EVOTEC BEI L&S +2,0% - FORTSCHRITTE MIT BRISTOL-MYERS-SQUIBB LÖSEN ZAHLUNG AUS |
05.06 13:43 | dpa-AFX: I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study |
03.06 18:26 | dpa-AFX: Bristol Myers' 3 Breyanzi Trials Show Consistent Benefit Across B-Cell Malignancies |
03.06 16:24 | dpa-AFX: *BRISTOL MYERS SQUIBB'S BREYANZI DATA SHOWS SIGNIFICANT BENEFITS ACROSS DIVERSE B-CELL MALIGNANCIES |
22.05 09:32 | dpa-AFX: *NEOPHORE CLOSES OVERSUBSCRIBED SERIES B EXTENSION ROUND WITH ADDITIONAL FUNDING FROM BRISTOL MYERS SQUIBB |
21.05 13:19 | dpa-AFX: *HALOZYME: BRISTOL MYERS SQUIBB GETS UPDATED ACTION DATE OF DEC. 29 FOR SUBCUTANEOUS NIVOLUMAB CO-FORMULATED WITH ENHANZE |
06.05 14:10 | dpa-AFX: Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation |
06.05 13:56 | dpa-AFX: *BMY :OPDIVO + YERVOY GRANTED EMA VALIDATION FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER |
30.04 19:48 | dpa-AFX: Biotech Stocks Facing FDA Decision In May 2024 |
29.04 12:26 | dpa-AFX: Repertoire Immune Medicines In Strategic Partnership With Bristol Myers Squibb |
29.04 12:02 | dpa-AFX: *REPERTOIRE® IMMUNE MEDICINES, BRISTOL MYERS SQUIBB ENTER STRATEGIC COLLABORATION TO DEVELOP TOLERIZING VACCINES |
|